These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9301438)

  • 1. EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer.
    Awada A; Van Vreckem A; Paridaens R; Bruning PF; Klijn J; Tomiak E; Vinholes J; Roy JA; Kusenda Z; Hoctin Boes G; Van Glabbeke M; Piccart MJ
    Eur J Cancer; 1997 Jul; 33(8):1173-6. PubMed ID: 9301438
    [No Abstract]   [Full Text] [Related]  

  • 2. One community. The B. Chevalier Lecture, held at the EORTC New Drugs Meeting, Lugano, Switzerland, 19-21 June 1997.
    Wittes RE; Yoder O
    Ann Oncol; 1998 Mar; 9(3):251-4. PubMed ID: 9602257
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
    Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
    Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European collaboration in trials of new agents for children with cancer.
    Ablett S; Doz F; Morland B; Vassal G; ;
    Eur J Cancer; 2004 Aug; 40(12):1886-92. PubMed ID: 15288291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new co-operative group: the European Myeloma Network Trialist Group.
    Leuk Lymphoma; 2009 Oct; 50(10):1581-8. PubMed ID: 19757308
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging drugs in metastatic breast cancer: an update.
    Arslan C; Altundag K; Dizdar O
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):647-67. PubMed ID: 22122529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation needed to optimise cancer drug development.
    Mayor S
    Lancet; 2004 Mar; 363(9414):1045. PubMed ID: 15065559
    [No Abstract]   [Full Text] [Related]  

  • 8. [Can new therapy concepts in oncology still be realized? Earlier death with standard therapy].
    Pickl S
    MMW Fortschr Med; 2002 Dec; 144(49):14. PubMed ID: 12577732
    [No Abstract]   [Full Text] [Related]  

  • 9. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 10. Single-Agent Abemaciclib Active in Breast Cancer.
    Cancer Discov; 2016 Aug; 6(8):809-10. PubMed ID: 27354271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer drugs in pipeline span wide spectrum.
    McCann J
    J Natl Cancer Inst; 2001 Mar; 93(6):424-6. PubMed ID: 11259465
    [No Abstract]   [Full Text] [Related]  

  • 12. European Commission considers revisions to clinical trials directive.
    Mason E
    J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of rational drug combinations with investigational targeted agents.
    Clark A; Ellis M; Erlichman C; Lutzker S; Zwiebel J
    Oncologist; 2010; 15(5):496-9. PubMed ID: 20489187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does a drug get to phase III trials?
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084
    [No Abstract]   [Full Text] [Related]  

  • 15. Epothilone D (Kosan/Roche).
    Kolman A
    Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
    Kalinsky K; Hershman DL
    J Comp Eff Res; 2013 Jul; 2(4):393-403. PubMed ID: 24236681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MS-209 Schering.
    Robert J
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 20. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.